ReviewCells2022
Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer's Disease.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- No evidence of major integrative brain clearance impairment in an Alzheimer´s disease model of transgenic APPswe/PS1dE9 mice.Fluids and barriers of the CNS · 2026Article
- Review
- Altered cerebrospinal fluid-based clearance mechanisms in aging autistic adults.Research square · 2026Article
- Choroidal-ventricular system abnormalities are linked to amyloid-β aggregation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Effects of spontaneous breathing anesthesia on postoperative cognitive dysfunction in elderly patients: a narrative review.Frontiers in surgery · 2026Review
- Choroid plexus enlargement is negatively associated with cognitive performance in a DTI-ALPS-dependent manner.Frontiers in aging neuroscience · 2026Article
- Review
- Hemodialysis and its effects on glymphatic system function in end-stage kidney disease patients.Quantitative imaging in medicine and surgery · 2025Article
- MRI markers of cerebrospinal fluid dynamics predict dementia and mediate the impact of cardiovascular risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The coupling of global brain activity and cerebrospinal fluid flow as a potential predictive marker of brain amyloid-β accumulation.The journal of prevention of Alzheimer's disease · 2025Observational
- Cerebral small vessel disease: The impact of glymphopathy and sleep disorders.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2025Review
- Identification of circadian-sensitive brain structure and its role in cognitive impairment and dementia.BMJ mental health · 2025Article
- Decreased Expression of Alzheimer's Disease-Related Genes in Cancer May Contribute to the Inverse-Relationship-a Computational Study.ACS omega · 2025Article
- The Gut-Brain Axis and Neuroinflammation in Traumatic Brain Injury.Molecular neurobiology · 2025Review
- The neurovascular unit and its correlation with cognitive performance in patients with cerebral small vessel disease: a canonical correlation analysis approach.GeroScience · 2024Article
- Coupling of Alzheimer's Disease Genetic Risk Factors with Viral Susceptibility and Inflammation.Aging and disease · 2024Review
- Clearance of extracellular human amyloid-β aggregates inmicroPublication biology · 2024Article
- An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer's Disease.Biomedicines · 2023Review
- The glymphatic system: a new perspective on brain diseases.Frontiers in aging neuroscience · 2023Review
- Early ultrasonic vocalization deficits and related thyroarytenoid muscle pathology in the transgenic TgF344-AD rat model of Alzheimer's disease.Frontiers in behavioral neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a multifactorial disease with a heterogeneous etiology. The pathology of Alzheimer's disease is characterized by amyloid-beta and hyperphosphorylated tau, which are necessary for disease progression. Many clinical trials on disease-modifying drugs for AD have failed to indicate their clinical benefits. Recent advances in fundamental research have indicated that neuroinflammation plays an important pathological role in AD. Damage- and pathogen-associated molecular patterns in the brain induce neuroinflammation and inflammasome activation, causing caspase-1-dependent glial and neuronal cell death. These waste products in the brain are eliminated by the glymphatic system via perivascular spaces, the blood-brain barrier, and the blood-cerebrospinal fluid barrier. Age-related vascular dysfunction is associated with an impairment of clearance and barrier functions, leading to neuroinflammation. The proteins involved in waste clearance in the brain and peripheral circulation may be potential biomarkers and drug targets in the early stages of cognitive impairment. This short review focuses on waste clearance dysfunction in AD pathobiology and discusses the improvement of waste clearance as an early intervention in prodromal AD and preclinical stages of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.